백신 시장 분석 및 예측(-2035년) : 유형별, 제품별, 기술별, 용도별, 최종 사용자별, 프로세스별, 도입 형태별, 재료 유형별, 디바이스별

Vaccines Market is anticipated to expand from $67.1 billion in 2024 to $138.0 billion by 2034, growing at a CAGR of approximately 8.1%. The Vaccines Market encompasses the development, production, and distribution of biological preparations that provide immunity against infectious diseases. It includes a diverse range of vaccines targeting viruses, bacteria, and other pathogens. The market is driven by advancements in biotechnology, rising incidence of infectious diseases, and government initiatives promoting immunization. Innovations in vaccine delivery systems, such as mRNA technology and needle-free administration, are pivotal in addressing global health challenges and expanding market opportunities.

The Vaccines Market is experiencing robust growth, propelled by advancements in biotechnology and increasing awareness of preventive healthcare. The infectious diseases segment leads the market, with vaccines for influenza and pneumococcal infections demonstrating top performance. These vaccines are critical in reducing disease burden and healthcare costs. The cancer vaccines sub-segment follows closely, driven by innovations in immunotherapy and personalized medicine. Therapeutic vaccines targeting specific cancer types are gaining momentum due to their potential to improve patient outcomes. The pediatric vaccines segment also shows significant promise, with routine immunizations for diseases like measles and polio maintaining high demand. Combination vaccines are emerging as a preferred choice, offering convenience and enhanced immunogenicity. The adult vaccines segment is expanding, with a focus on boosting immunity against diseases such as shingles and hepatitis. Continuous research and development, alongside strategic collaborations, are vital in sustaining market growth and addressing unmet medical needs.

The vaccines market is characterized by a diverse array of players, each vying for market share through competitive pricing strategies and innovative product launches. The dynamic landscape is influenced by the introduction of novel vaccines addressing emerging health threats. Companies are strategically adjusting pricing to enhance accessibility while maintaining profitability. The continuous development of new formulations and delivery systems underscores the industry's commitment to innovation and public health. Competition within the vaccines market is intense, with key players striving for differentiation through research and development. Regulatory influences are significant, with stringent guidelines impacting the pace of new product approvals. The competitive landscape is shaped by industry giants and emerging biotech firms, each leveraging scientific advancements to gain a competitive edge. Regulatory frameworks in regions such as North America and Europe are pivotal, shaping market dynamics and influencing strategic decisions. The interplay between regulation and innovation is crucial in determining market trajectories.

Geographical Overview:

The vaccines market is witnessing robust growth across diverse regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and substantial public and private investments in vaccine development. The region's focus on innovation and rapid adoption of new technologies bolsters its market position. Europe follows closely, with strong government support for vaccination programs and a well-established pharmaceutical industry. The region's commitment to public health and research excellence further enhances its market dynamics. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and a growing population. Countries such as China and India emerge as key growth pockets, with significant investments in vaccine research and manufacturing capabilities. Latin America and the Middle East & Africa are emerging markets with considerable potential. In Latin America, rising healthcare awareness and government initiatives drive market growth, while in the Middle East & Africa, improving healthcare infrastructure and increased vaccination efforts present new opportunities.

The global vaccines market is increasingly influenced by tariff impositions and geopolitical tensions, particularly in East Asia. Japan and South Korea are navigating these challenges by enhancing domestic vaccine production capabilities and fostering regional collaborations. China, amid trade tensions, accelerates its vaccine R&D and manufacturing self-sufficiency, while Taiwan focuses on maintaining its strategic position in biotech innovation. The parent market is buoyant, driven by heightened demand for vaccines and technological advancements. By 2035, the market is projected to thrive on diversified supply chains and cross-border partnerships. Meanwhile, Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy costs, indirectly impacting production and distribution logistics. These dynamics necessitate strategic agility and robust risk management for sustained market growth.

Key Trends and Drivers:

The vaccines market is experiencing robust growth, propelled by heightened global health awareness and the urgent need for pandemic preparedness. Key trends include the accelerated development of mRNA vaccines, which offer rapid response capabilities and strong efficacy. Governments are investing heavily in vaccine research and manufacturing infrastructure, ensuring swift responses to emerging health threats. Drivers include the rising prevalence of infectious diseases and the expanding immunization programs worldwide. Public-private partnerships are fostering innovation and facilitating the distribution of vaccines, particularly in low-income regions. The emphasis on personalized medicine is also encouraging the development of vaccines tailored to specific populations, enhancing their effectiveness. Moreover, technological advancements in biotechnology and genomics are enabling the creation of next-generation vaccines with improved safety profiles. Opportunities abound in emerging markets where vaccination coverage is increasing. Companies focusing on innovative delivery systems and expanding their global footprint are well-positioned to capitalize on these trends. As the world continues to grapple with health challenges, the vaccines market is poised for sustained expansion, driven by scientific breakthroughs and international collaborations.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Deployment
• 2.8 Key Market Highlights by Material Type
• 2.9 Key Market Highlights by Device

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Live Attenuated Vaccines
  • 4.1.2 Inactivated Vaccines
  • 4.1.3 Subunit Vaccines
  • 4.1.4 Toxoid Vaccines
  • 4.1.5 Conjugate Vaccines
  • 4.1.6 DNA Vaccines
  • 4.1.7 Recombinant Vector Vaccines
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Human Vaccines
  • 4.2.2 Animal Vaccines
  • 4.2.3 Pediatric Vaccines
  • 4.2.4 Adult Vaccines
  • 4.2.5 Travel Vaccines
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Recombinant Technology
  • 4.3.2 Cell Culture Technology
  • 4.3.3 Gene Editing Technology
  • 4.3.4 Nanoparticle Technology
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Infectious Diseases
  • 4.4.2 Cancer
  • 4.4.3 Allergies
  • 4.4.4 Neurological Disorders
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Pharmaceutical Companies
  • 4.5.5 Biotechnology Companies
  • 4.5.6 Government Organizations
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Research and Development
  • 4.6.2 Manufacturing
  • 4.6.3 Distribution
• 4.7 Market Size & Forecast by Deployment (2020-2035)
  • 4.7.1 On-Premise
  • 4.7.2 Cloud-Based
• 4.8 Market Size & Forecast by Material Type (2020-2035)
  • 4.8.1 Biological
  • 4.8.2 Synthetic
• 4.9 Market Size & Forecast by Device (2020-2035)
  • 4.9.1 Syringes
  • 4.9.2 Needle-Free Injectors

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Deployment
    • 5.2.1.8 Material Type
    • 5.2.1.9 Device
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Deployment
    • 5.2.2.8 Material Type
    • 5.2.2.9 Device
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Deployment
    • 5.2.3.8 Material Type
    • 5.2.3.9 Device
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Deployment
    • 5.3.1.8 Material Type
    • 5.3.1.9 Device
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Deployment
    • 5.3.2.8 Material Type
    • 5.3.2.9 Device
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Deployment
    • 5.3.3.8 Material Type
    • 5.3.3.9 Device
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Deployment
    • 5.4.1.8 Material Type
    • 5.4.1.9 Device
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Deployment
    • 5.4.2.8 Material Type
    • 5.4.2.9 Device
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Deployment
    • 5.4.3.8 Material Type
    • 5.4.3.9 Device
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Deployment
    • 5.4.4.8 Material Type
    • 5.4.4.9 Device
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Deployment
    • 5.4.5.8 Material Type
    • 5.4.5.9 Device
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Deployment
    • 5.4.6.8 Material Type
    • 5.4.6.9 Device
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Deployment
    • 5.4.7.8 Material Type
    • 5.4.7.9 Device
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Deployment
    • 5.5.1.8 Material Type
    • 5.5.1.9 Device
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Deployment
    • 5.5.2.8 Material Type
    • 5.5.2.9 Device
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Deployment
    • 5.5.3.8 Material Type
    • 5.5.3.9 Device
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Deployment
    • 5.5.4.8 Material Type
    • 5.5.4.9 Device
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Deployment
    • 5.5.5.8 Material Type
    • 5.5.5.9 Device
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Deployment
    • 5.5.6.8 Material Type
    • 5.5.6.9 Device
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Deployment
    • 5.6.1.8 Material Type
    • 5.6.1.9 Device
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Deployment
    • 5.6.2.8 Material Type
    • 5.6.2.9 Device
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Deployment
    • 5.6.3.8 Material Type
    • 5.6.3.9 Device
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Deployment
    • 5.6.4.8 Material Type
    • 5.6.4.9 Device
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Deployment
    • 5.6.5.8 Material Type
    • 5.6.5.9 Device

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Sinovac Biotech
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Bharat Biotech
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Cure Vac
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Novavax
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Valneva
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Emergent Bio Solutions
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 VBI Vaccines
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Dynavax Technologies
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Inovio Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Geo Vax Labs
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Moderna
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bio NTech
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Sanofi Pasteur
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Glaxo Smith Kline
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Pfizer
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Astra Zeneca
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Johnson & Johnson
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Merck & Co
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 CSL Limited
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Seqirus
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us